A Phase II Trial of Tricyclic Nucleoside Phosphate in Patients with Advanced Squamous Cell Carcinoma of the Cervix
- 1 December 1993
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 16 (6) , 506-508
- https://doi.org/10.1097/00000421-199312000-00010
Abstract
A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 × 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.Keywords
This publication has 0 references indexed in Scilit: